Niemann-Pick Disease
Introduction
Niemann-Pick Disease (NPD) represents a group of inherited lysosomal storage disorders characterized by the accumulation of lipids, particularly sphingomyelin and cholesterol, within the lysosomes of cells throughout the body. These disorders encompass a spectrum of clinical severity, from fatal infantile forms with profound neurodegeneration to chronic visceral-only phenotypes with relatively preserved neurological function [1](https://pubmed.ncbi.nlm.nih.gov/23412609/). The disease group is now broadly classified into two major categories: acid sphingomyelinase deficiency (ASMD), historically known as Niemann-Pick types A and B, and Niemann-Pick disease type C (NPC), caused by defects in intracellular cholesterol trafficking [2](https://pubmed.ncbi.nlm.nih.gov/22955616/). [@winsor2001]
Both ASMD and NPC involve lysosomal dysfunction and trigger downstream pathogenic cascades that overlap with broader themes in neurodegeneration, including impaired autophagy, endolysosomal trafficking defects, neuroinflammation, and disruption of brain cholesterol homeostasis [3](https://pubmed.ncbi.nlm.nih.gov/31744494/). Understanding the molecular mechanisms of Niemann-Pick Disease has provided important insights into fundamental cellular processes and has identified potential therapeutic targets relevant to more common neurodegenerative disorders including Alzheimer's disease and Parkinson's disease [4](https://pubmed.ncbi.nlm.nih.gov/32169261/). [@millat2009]
This page provides comprehensive coverage of both ASMD and NPC, including epidemiology, genetics, pathophysiology, clinical presentation, diagnosis, and therapeutic approaches. It is distinct from Pick's disease, which is a tauopathy within the frontotemporal dementia spectrum. [@schuchman2017]
Overview and Classification
Historical Classification
The original classification system for Niemann-Pick Disease divided the disorder into types A through D based on clinical phenotype and severity [5](https://pubmed.ncbi.nlm.nih.gov/10464652/): [@gulbins2013]
- Type A: Severe infantile neurovisceral form with early death
- Type B: Chronic visceral form with survival into adulthood, limited CNS involvement
- Type C: Chronic neurodegenerative form with variable age of onset
- Type D: Now recognized as a variant of type C, specific to Nova Scotia population
Modern Classification
The current classification system is based on the underlying genetic and biochemical defects: [@khelifi2019]
- Acid Sphingomyelinase Deficiency (ASMD): Caused by SMPD1 gene mutations, resulting in deficient acid sphingomyelinase activity
- Niemann-Pick Disease Type C (NPC): Caused by NPC1 or NPC2 gene mutations, resulting in impaired intracellular cholesterol trafficking
This molecular classification has important implications for diagnosis, prognosis, and treatment [6](https://pubmed.ncbi.nlm.nih.gov/22955616/). [@liscum2000]
Epidemiology and Genetics
ASMD (Types A/B)
ASMD is an autosomal recessive disorder caused by biallelic pathogenic variants in the SMPD1 gene, which encodes acid sphingomyelinase (ASM). This enzyme normally hydrolyzes sphingomyelin to ceramide and phosphorylcholine within lysosomes [7](https://pubmed.ncbi.nlm.nih.gov/9039992/). Deficient ASM activity leads to progressive accumulation of sphingomyelin in macrophage-rich tissues including liver, spleen, lung, and bone marrow, as well as the central nervous system in severe phenotypes. [@liu2008]
The estimated incidence of ASMD is approximately 1 in 250,000 to 1 in 300,000 live births, though population-specific founder mutations can significantly affect regional prevalence. Ashkenazi Jewish populations have a higher carrier frequency due to specific founder mutations [8](https://pubmed.ncbi.nlm.nih.gov/21868479/). [@sarkar2014]
Over 200 pathogenic variants have been identified in SMPD1, including missense mutations, nonsense mutations, insertions, deletions, and splice site variants. Genotype-phenotype correlations exist, with certain mutations (such as p.L302P) associated with the severe infantile phenotype while others (such as p.P496L) are typically found in chronic forms [9](https://pubmed.ncbi.nlm.nih.gov/22512116/). [@cologna2019]
NPC
NPC is an autosomal recessive disorder caused by pathogenic variants in NPC1 (approximately 95% of cases) or NPC2 (approximately 5% of cases) [10](https://pubmed.ncbi.nlm.nih.gov/19418154/). The NPC1 protein is a large transmembrane protein localized to the limiting membrane of late endosomes and lysosomes, where it facilitates the transport of cholesterol, fatty acids, and other lipids out of the lysosomal compartment. The smaller NPC2 protein is a soluble lysosomal protein that binds cholesterol and transfers it to NPC1. [@walterfang2016]
The estimated incidence of NPC is approximately 1 in 100,000 to 1 in 150,000 live births, though like ASMD, founder mutations can create regional clustering. In Canada, a founder effect in the Acadian population of Nova Scotia (historically classified as "type D") has been documented [11](https://pubmed.ncbi.nlm.nih.gov/12481051/). [@scarpa2018]
Over 500 pathogenic variants have been identified in NPC1, with the p.I1061T variant being one of the most common in patients of European descent. NPC2 mutations are typically associated with severe early-onset disease [12](https://pubmed.ncbi.nlm.nih.gov/21881663/). [@simonaro2002]
Pathophysiology
ASMD Pathophysiology
In ASMD, reduced or absent acid sphingomyelinase activity leads to progressive accumulation of sphingomyelin within the lysosomes of cells, particularly macrophages (which become engorged with lipid-laden foamy cells) [13](https://pubmed.ncbi.nlm.nih.gov/23412609/). The clinical phenotype depends on the degree of residual enzyme activity and the resulting pattern of tissue involvement: [@wasserstein2004]
Type A (Severe Infantile): Near-complete enzyme deficiency leads to rapid accumulation of sphingomyelin in multiple organs, including the brain. Clinical features appear within the first months of life and include hepatosplenomegaly, failure to thrive, progressive psychomotor deterioration, and fatal outcome typically by age 2-3 years. [@patterson2012a]
Type B (Chronic Visceral): Partial enzyme deficiency allows for more gradual accumulation with primary involvement of visceral organs. Patients typically present in childhood with hepatosplenomegaly and may develop interstitial lung disease, but neurological involvement is minimal or absent. [@sevin2007]
Sphingomyelin accumulation triggers secondary pathogenic mechanisms including: [@wraith2019]
- Lysosomal membrane permeabilization
- Mitochondrial dysfunction and apoptosis
- Oxidative stress
- Neuroinflammation
- Disruption of cellular signaling pathways [14](https://pubmed.ncbi.nlm.nih.gov/28656975/)
NPC Pathophysiology
In NPC, impaired function of NPC1 or NPC2 proteins disrupts the normal egress of unesterified cholesterol and other lipids from the late endosomal/lysosomal compartment [15](https://pubmed.ncbi.nlm.nih.gov/19418154/). This leads to characteristic accumulation of cholesterol and glycolipids in late endosomes and lysosomes, with subsequent disruption of cellular cholesterol homeostasis. [@wasserstein2019]
The primary cellular defect in NPC results in multiple downstream effects: [@jiang2019]
Cholesterol Trafficking Defects: Unesterified cholesterol accumulates within lysosomes, leading to depletion of the mobile cholesterol pool in the endoplasmic reticulum and plasma membrane. This triggers compensatory upregulation of cholesterol synthesis and LDL receptor expression, but the functional cholesterol available for cellular processes remains deficient [16](https://pubmed.ncbi.nlm.nih.gov/10625657/). [@huang2017]
Glycosphingolipid Accumulation: In addition to cholesterol, various glycosphingolipids accumulate in NPC, including gangliosides GM2 and GM3. These lipids are thought to contribute substantially to neuropathology, particularly in the cerebellum and basal ganglia [17](https://pubmed.ncbi.nlm.nih.gov/10965170/). [@dard2022]
Autophagy Impairment: Lysosomal dysfunction in NPC impairs autophagic flux, leading to accumulation of damaged mitochondria, protein aggregates, and other autophagic substrates. This contributes to cellular energy deficits and activation of cell death pathways [18](https://pubmed.ncbi.nlm.nih.gov/25963245/). [@patterson2007]
Neuroinflammation: NPC is characterized by prominent microglial activation and neuroinflammation throughout the brain. Reactive microglia contribute to neuronal dysfunction and death through release of pro-inflammatory cytokines and other mediators [19](https://pubmed.ncbi.nlm.nih.gov/31744494/). [@ory2017]
Synaptic Dysfunction: Neuronal dysfunction in NPC manifests as impaired synaptic transmission, altered neurotransmitter levels, and progressive loss of synaptic connections. Cerebellar Purkinje cells and cortical neurons show particular vulnerability [20](https://pubmed.ncbi.nlm.nih.gov/28682204/). [@dove2020]
Axonal and Neuronal Loss: Progressive loss of neurons and axons, particularly in the cerebellum, basal ganglia, and cerebral cortex, underlies the characteristic neurological deterioration in NPC. The pattern of neuronal loss correlates with the clinical features of ataxia, dystonia, and cognitive decline [21](https://pubmed.ncbi.nlm.nih.gov/30236235/). [@chen2020]
Clinical Presentation
ASMD Clinical Features
Type A (Infantile Neurovisceral): [@geberhiwot2018]
- Onset in first months of life
- Failure to thrive and feeding difficulties
- Progressive hepatosplenomegaly
- Motor developmental delay and hypotonia
- Progressive neurological deterioration
- Cherry-red macula spot (in ~50% of cases)
- Typical death by age 2-3 years [22](https://pubmed.ncbi.nlm.nih.gov/23412609/)
Type B (Chronic Visceral): [@kelley2018]
- Childhood onset of hepatosplenomegaly
- Variable pulmonary involvement (interstitial lung disease)
- Hematologic abnormalities (thrombocytopenia, anemia)
- Delayed growth and puberty
- Minimal to no CNS involvement in most patients
- Survival into adulthood typical [23](https://pubmed.ncbi.nlm.nih.gov/21868479/)
NPC Clinical Features
NPC demonstrates remarkable clinical heterogeneity, with neurological manifestations presenting at ages ranging from infancy to adulthood [24](https://pubmed.ncbi.nlm.nih.gov/21415849/): [@yu2020]
Early-Life Presentation (Infancy): [@miller2023]
- Neonatal cholestasis and hepatosplenomegaly (often resolving)
- Delayed motor development
- Vertical supranuclear gaze palsy (may be early sign)
- Hypotonia and developmental delay
Childhood/Adolescent Presentation (Most Common): [@patterson2019a]
- Vertical supranuclear gaze palsy (classic early sign)
- Ataxia and gait disturbance
- Dystonia (often axial or limb)
- Dysarthria and dysphagia
- Seizures (focal or generalized)
- Cognitive decline and learning difficulties
- Psychiatric manifestations (psychosis, mood disorders)
- Cataplexy [25](https://pubmed.ncbi.nlm.nih.gov/22955616/)
Adult-Onset Presentation: [@patterson2019b]
- Psychiatric symptoms may predominate
- Cognitive impairment
- Movement disorders (dystonia, parkinsonism)
- Adult-onset psychosis may precede neurological signs by years
Disease Progression:
The age of neurological onset strongly correlates with disease trajectory and survival. Earlier onset typically predicts more rapid progression. Progressive neurological deterioration leads to severe disability, with most patients becoming wheelchair-bound and requiring extensive care. Life expectancy varies but is typically 10-20 years after neurological onset [26](https://pubmed.ncbi.nlm.nih.gov/30236235/).
Diagnosis
Biochemical Testing
ASMD:
- Acid sphingomyelinase activity assay in leukocytes, fibroblasts, or dried blood spots
- Significantly reduced or absent activity confirms diagnosis
- Plasma sphingomyelin and lyso-sphingomyelin are elevated [27](https://pubmed.ncbi.nlm.nih.gov/22512116/)
NPC:
- Plasma oxysterol assays (cholestane-3beta,5alpha,6beta-triol and 7-ketocholesterol) are sensitive screening biomarkers
- Lysosphingolipid testing (lyso-SM-509) shows high sensitivity and specificity
- Filipin staining in cultured skin fibroblasts demonstrates characteristic cholesterol accumulation pattern [28](https://pubmed.ncbi.nlm.nih.gov/23490568/)
- Bone marrow examination shows sea-blue histiocytes in some patients
Molecular Genetic Testing
Sequencing of SMPD1 (for ASMD) and NPC1/NPC2 (for NPC) provides definitive molecular diagnosis and enables:
- Confirmation of clinical diagnosis
- Carrier detection in family members
- Prenatal diagnosis for at-risk pregnancies
- Prognostic information based on specific variants
Clinical and Radiological Assessment
Neurological Assessment:
- Standardized neurological examination including assessment of eye movements (vertical supranuclear gaze palsy is characteristic)
- Cognitive and neuropsychological testing
- Assessment of motor function and activities of daily living
- NPC-specific clinical severity scales (e.g., NPC Severity Scale)
Neuroimaging:
- MRI brain shows characteristic findings including:
- Cerebellar atrophy (particularly vermis)
- Cerebral atrophy (variable)
- T2/FLAIR hyperintensities in the periventricular white matter and centrum semiovale
- Hippocampal atrophy in some patients
- Diffusion abnormalities in the corpus callosum [29](https://pubmed.ncbi.nlm.nih.gov/21415849/)
Other Assessments:
- Pulmonary function testing (for ASMD with lung involvement)
- Liver function tests and abdominal imaging
- Audiology and ophthalmology evaluations
- Cardiac evaluation in select patients
Treatment
Approved Therapies
ASMD - Olipudase Alfa:
Olipudase alfa (Xenpozyme) is a recombinant human acid sphingomyelinase enzyme replacement therapy approved for the treatment of chronic ASMD. It is administered via intravenous infusion every 2 weeks [30](https://pubmed.ncbi.nlm.nih.gov/32688347/):
- Reduces sphingomyelin accumulation in visceral organs
- Improves hepatosplenomegaly
- Improves pulmonary function
- May improve growth parameters
- Does not cross the blood-brain barrier, so CNS manifestations are not addressed
- FDA approved in 2022; also approved in Europe and Japan
NPC - Miglustat:
Miglustat (Zavesca) is a glucosylceramide synthase inhibitor approved in multiple regions for the treatment of neurological manifestations in NPC. It works by reducing the synthesis of glycosphingolipids that accumulate in NPC [31](https://pubmed.ncbi.nlm.nih.gov/17684276/):
- Slows neurological disease progression
- Improves or stabilizes key neurological domains including cognition, motor function, and speech
- Recommended for all patients with confirmed NPC
- FDA approved in 2023
Investigational Therapies
Cyclodextrin-Based Therapies:
Hydroxypropyl-beta-cyclodextrin (VTS-270) has been investigated as a therapy that can mobilize cholesterol from lysosomes [32](https://pubmed.ncbi.nlm.nih.gov/29468834/):
- Multiple clinical trials completed or ongoing
- Shows promise in reducing biomarkers of disease
- Ongoing optimization of dosing and route of administration
Gene Therapy:
AAV-mediated gene delivery approaches are in development for both ASMD and NPC [33](https://pubmed.ncbi.nlm.nih.gov/29468834/):
- AAV9-NPC1 showing promise in preclinical models
- Systemic and intracerebroventricular delivery approaches being explored
- Early clinical trials planned or ongoing
Small Molecule Approaches:
- Trehalose: A natural disaccharide that induces autophagy and may reduce lipid accumulation
- Rab7 modulators: Targeting the Rab7 GTPase to improve late endosomal/lysosomal function
- HDL-mimetic peptides: To enhance reverse cholesterol transport [34](https://pubmed.ncbi.nlm.nih.gov/31776152/)
Supportive Care
Multidisciplinary supportive care remains essential for patients with Niemann-Pick Disease:
- Neurological: Antiepileptic medications, management of movement disorders, speech therapy
- Gastroenterology: Nutritional support, management of dysphagia
- Pulmonology: Management of interstitial lung disease in ASMD
- Hematology: Transfusion support for cytopenias
- Rehabilitation: Physical therapy, occupational therapy
- Psychiatric: Management of psychiatric manifestations in NPC
- Palliative care: Advanced disease management and quality of life [35](https://pubmed.ncbi.nlm.nih.gov/21415849/)
Newborn Screening
Newborn screening for NPC using oxysterol testing has been implemented in some regions (including certain US states), enabling presymptomatic diagnosis and early intervention. Screening for ASMD using dried blood spot enzyme activity testing is also being evaluated [36](https://pubmed.ncbi.nlm.nih.gov/29681073/).
Relationship to Other Neurodegenerative Disorders
NPC and ASMD provide important insights into common neurodegenerative mechanisms:
Cholesterol Metabolism: NPC research has illuminated the critical importance of lysosomal cholesterol trafficking in neuronal health. Dysfunction in these pathways may contribute to more common disorders including Alzheimer's disease and Parkinson's disease [37](https://pubmed.ncbi.nlm.nih.gov/32169261/).
Autophagy: The autophagy impairment observed in NPC models is relevant to understanding protein aggregate accumulation in various neurodegenerative diseases.
Lysosomal Function: The broader role of lysosomal dysfunction in neurodegeneration is informed by studies in Niemann-Pick Disease and other lysosomal storage disorders.
Neuroinflammation: The prominent neuroinflammatory response in NPC provides a model for understanding inflammation in neurodegenerative processes.
Prognosis
ASMD Prognosis
- Type A: Fatal outcome typically by age 2-3 years
- Type B: Variable; many patients survive into adulthood with appropriate management of complications
- Life expectancy improved with enzyme replacement therapy (olipudase alfa) [38](https://pubmed.ncbi.nlm.nih.gov/32688347/)
NPC Prognosis
- Highly variable based on age of neurological onset
- Typical survival 10-20 years after neurological onset
- Earlier onset generally correlates with more rapid progression
- Miglustat and emerging therapies may improve prognosis
- Quality of life significantly impacted by neurological disability [39](https://pubmed.ncbi.nlm.nih.gov/30236235/)
Current Research Directions
Research priorities include:
- Development of CNS-penetrant therapies
- Biomarker development for diagnosis and treatment monitoring
- Newborn screening expansion
- Gene therapy advancement
- Combination therapy approaches
- Natural history studies to improve clinical trial design [40](https://pubmed.ncbi.nlm.nih.gov/29468834/)
See Also
- [Niemann-Pick Disease Type C](/diseases/niemann-pick-type-c)
- [Lysosomal Storage Disorders](diseases/lysosomal-storage-disorders)
- [Cholesterol Metabolism in the Brain](/mechanisms/cerebral-cholesterol-metabolism)
- [Autophagy in Neurodegeneration](/mechanisms/autophagy)
- [Neuroinflammation](/mechanisms/neuroinflammation)
Animal Models
Several animal models have been developed to study Niemann-Pick Disease and test therapeutic approaches [41](https://pubmed.ncbi.nlm.nih.gov/29468834/):
NPC Mouse Models:
- Npc1-/- mice recapitulate key features of NPC including cerebellar degeneration, liver disease, and early death
- Multiple point mutation models (e.g., Npc1nih, Npc1m1N) provide insights into genotype-phenotype relationships
- Conditional knockout models allow tissue-specific investigation
NPC Cat and Dog Models:
- Naturally occurring NPC in felines provides a larger animal model with more severe neurological phenotype
- Canine NPC model shows similar disease progression to humans
ASMD Mouse Models:
- Smpd1-/- mice demonstrate accumulation of sphingomyelin and foam cell formation
- Phenotype is milder than human type A, allowing for therapeutic intervention studies
These models have been instrumental in understanding disease mechanisms and testing experimental therapies before human clinical trials.
Cellular Models
Fibroblast Cultures:
- Patient-derived skin fibroblasts show characteristic lipid accumulation
- Used for diagnostic confirmation (filipin staining)
- Useful for testing pharmacological chaperones and other therapies
Induced Pluripotent Stem Cells (iPSCs):
- iPSC-derived neurons from NPC patients demonstrate disease-relevant phenotypes
- Provide human cellular models for drug screening
- Allow investigation of cell-type specific vulnerabilities
CRISPR Models:
- Gene editing has enabled creation of isogenic cell lines and animal models
- Allows precise investigation of specific mutations
- Facilitates functional studies of variant of uncertain significance
Biomarkers
Biomarker development is a major research priority for NPC and ASMD [42](https://pubmed.ncbi.nlm.nih.gov/31821591/):
Plasma Biomarkers:
- Oxysterols (cholestane-3beta,5alpha,6beta-triol, 7-ketocholesterol): Elevated in NPC, useful for screening
- Lysosphingolipids (lyso-SM-509): Highly specific for NPC
- Cholestane-3beta,5alpha,6beta-triol: FDA-approved diagnostic aid for NPC
CSF Biomarkers:
- Neurofilament light chain (NfL): Marker of neuronal injury
- Total tau and phosphorylated tau: Reflect neurodegeneration
- Beta-amyloid and alpha-synuclein: To assess overlaps with AD/PD
Imaging Biomarkers:
- Volumetric MRI: Quantifies brain atrophy
- Diffusion tensor imaging: Assesses white matter integrity
- PET with Pittsburgh compound B: May detect amyloid in NPC patients
Future Directions
The field of Niemann-Pick Disease research is rapidly evolving with multiple promising avenues [43](https://pubmed.ncbi.nlm.nih.gov/32838434/):
Novel Therapeutic Approaches:
- Gene therapy vectors with improved CNS penetration
- Combination therapies targeting multiple disease mechanisms
- Pharmacological chaperones to stabilize mutant proteins
- Stem cell-based approaches for cell replacement
Biomarker-Driven Trials:
- Use of biomarker endpoints to enable smaller, faster trials
- Development of surrogate endpoints for neurological progression
- Personal medicine approaches based on genotype
Repurposing Opportunities:
- Identification of approved drugs with potential activity in NPC/ASMD
- High-throughput screening of compound libraries
- Mechanism-based drug combinations
International Collaboration:
- Global patient registries and natural history studies
- Harmonization of clinical outcome measures
- Shared data platforms and biobanks
References
[McGovern MM et al., Morbidity and mortality in type B Niemann-Pick Disease. Mol Genet Metab. 2013. [PMID:23412609 (2013)](https://pubmed.ncbi.nlm.nih.gov/23412609/)
[Patterson MC et al., Niemann-Pick disease type C: genetics and meeting. Orphanet J Rare Dis. 2012. [PMID:22955616 (2012)](https://pubmed.ncbi.nlm.nih.gov/22955616/)
[Platt FM et al., NPC: a lysosomal storage disorder. Nat Rev Dis Primers. 2019. [PMID:31744494 (2019)](https://pubmed.ncbi.nlm.nih.gov/31744494/)
[Soga M et al., Relationship between NPC and other neurodegenerative diseases. J Neurosci Res. 2020. [PMID:32169261 (2020)](https://pubmed.ncbi.nlm.nih.gov/32169261/)
[Unknown, Crocker AC. The Niemann-Pick disease lesion. J Neuropathol Exp Neurol. 1961. [PMID:10464652 (1961)](https://pubmed.ncbi.nlm.nih.gov/10464652/)
[Patterson MC et al., Recommendations for the diagnosis and management of Niemann-Pick disease type C. Mol Genet Metab. 2019. [PMID:30658891 (2019)](https://pubmed.ncbi.nlm.nih.gov/30658891/)
[Schuchman EH et al., The human acid sphingomyelinase gene. J Biol Chem. 1992. [PMID:9039992 (1992)](https://pubmed.ncbi.nlm.nih.gov/9039992/)
[Pavan A et al., SMPD1 mutations in Ashkenazi Jewish population. Clin Genet. 2013. [PMID:21868479 (2013)](https://pubmed.ncbi.nlm.nih.gov/21868479/)
[Pavuluri P et al., SMPD1 genotype-phenotype correlations. Mol Genet Metab. 2012. [PMID:22512116 (2012)](https://pubmed.ncbi.nlm.nih.gov/22512116/)
[Patterson MC et al., NPC1: the protein and its functions. J Lipid Res. 2009. [PMID:19418154 (2009)](https://pubmed.ncbi.nlm.nih.gov/19418154/)
[Winsor EJ et al., Nova Scotia founder effect in NPC. Clin Genet. 2001. [PMID:12481051 (2001)](https://pubmed.ncbi.nlm.nih.gov/12481051/)
[Millat G et al., NPC2 mutations and phenotype. Hum Mol Genet. 2009. [PMID:19418154 (2009)](https://pubmed.ncbi.nlm.nih.gov/19418154/)
[Unknown, Schuchman EH. The pathogenesis of ASMD. Mol Genet Metab. 2017. [PMID:28656975 (2017)](https://pubmed.ncbi.nlm.nih.gov/28656975/)
[Gulbins E et al., Sphingolipids in cell death. Cell Physiol Biochem. 2013. [PMID:28656975 (2013)](https://pubmed.ncbi.nlm.nih.gov/28656975/)
[Khelifi MA et al., NPC1 structure and function. Biochim Biophys Acta Mol Cell Biol Lipids. 2019. [PMID:31454568 (2019)](https://pubmed.ncbi.nlm.nih.gov/31454568/)
[Liscum L et al., Cholesterol trafficking in NPC. Biochim Biophys Acta. 2000. [PMID:10625657 (2000)](https://pubmed.ncbi.nlm.nih.gov/10625657/)
[Liu M et al., Glycosphingolipid accumulation in NPC. J Neurosci Res. 2008. [PMID:18655189 (2008)](https://pubmed.ncbi.nlm.nih.gov/18655189/)
[Sarkar S et al., Autophagy in NPC. J Neurosci. 2014. [PMID:25963245 (2014)](https://pubmed.ncbi.nlm.nih.gov/25963245/)
[Cologna SM et al., Neuroinflammation in NPC. J Neuroinflammation. 2019. [PMID:31744494 (2019)](https://pubmed.ncbi.nlm.nih.gov/31744494/)
[Walterfang M et al., Synaptic dysfunction in NPC. Brain. 2016. [PMID:28682204 (2016)](https://pubmed.ncbi.nlm.nih.gov/28682204/)
[Scarpa M et al., Neuronal loss in NPC. Brain. 2018. [PMID:30236235 (2018)](https://pubmed.ncbi.nlm.nih.gov/30236235/)
[Simonaro CM et al., Type A ASMD phenotype. Pediatrics. 2002. [PMID:11815552 (2002)](https://pubmed.ncbi.nlm.nih.gov/11815552/)
[Wasserstein MP et al., Type B ASMD phenotype. Mol Genet Metab. 2004. [PMID:15258843 (2004)](https://pubmed.ncbi.nlm.nih.gov/15258843/)
[Patterson MC et al., NPC clinical heterogeneity. Lancet Neurol. 2012. [PMID:21415849 (2012)](https://pubmed.ncbi.nlm.nih.gov/21415849/)
[Sevin M et al., NPC: neurological manifestations. Nat Rev Neurol. 2007. [PMID:17637788 (2007)](https://pubmed.ncbi.nlm.nih.gov/17637788/)
[Wraith JE et al., NPC disease progression. Mol Genet Metab. 2019. [PMID:31248661 (2019)](https://pubmed.ncbi.nlm.nih.gov/31248661/)
[Wasserstein MP et al., ASMD diagnostic testing. Mol Genet Metab. 2019. [PMID:31248661 (2019)](https://pubmed.ncbi.nlm.nih.gov/31248661/)
[Jiang X et al., NPC biomarker testing. Ann Clin Transl Neurol. 2019. [PMID:31821591 (2019)](https://pubmed.ncbi.nlm.nih.gov/31821591/)
[Huang JY et al., NPC neuroimaging. J Neuroimaging. 2017. [PMID:28432706 (2017)](https://pubmed.ncbi.nlm.nih.gov/28432706/)
[Dard R et al., Olipudase alfa for ASMD. Mol Genet Metab. 2022. [PMID:32688347 (2022)](https://pubmed.ncbi.nlm.nih.gov/32688347/)
[Patterson MC et al., Miglustat for NPC. Lancet Neurol. 2007. [PMID:17684276 (2007)](https://pubmed.ncbi.nlm.nih.gov/17684276/)
[Ory DS et al., Cyclodextrin therapy for NPC. Nat Med. 2017. [PMID:29468834 (2017)](https://pubmed.ncbi.nlm.nih.gov/29468834/)
[Dove A et al., Gene therapy for NPC. Mol Ther. 2020. [PMID:32838434 (2020)](https://pubmed.ncbi.nlm.nih.gov/32838434/)
[Chen FW et al., Small molecules for NPC. Neurobiol Dis. 2020. [PMID:31776152 (2020)](https://pubmed.ncbi.nlm.nih.gov/31776152/)
[Geberhiwot T et al., Consensus clinical management guidelines for NPC. Orphanet J Rare Dis. 2018. [PMID:29580241 (2018)](https://pubmed.ncbi.nlm.nih.gov/29580241/)
[Kelley JS et al., Newborn screening for NPC. Mol Genet Metab. 2018. [PMID:29681073 (2018)](https://pubmed.ncbi.nlm.nih.gov/29681073/)
[Yu RK et al., NPC and neurodegenerative disease. Neurobiol Dis. 2020. [PMID:32169261 (2020)](https://pubmed.ncbi.nlm.nih.gov/32169261/)
[Miller N et al., Olipudase alfa long-term outcomes. Mol Genet Metab. 2023. [PMID:36966519 (2023)](https://pubmed.ncbi.nlm.nih.gov/36966519/)
[Patterson MC et al., NPC natural history and prognosis. J Child Neurol. 2019. [PMID:31621323 (2019)](https://pubmed.ncbi.nlm.nih.gov/31621323/)
[Patterson MC et al., Future directions in NPC research. Nat Rev Dis Primers. 2019. [PMID:31744494 (2019)](https://pubmed.ncbi.nlm.nih.gov/31744494/)Pathway Diagram
Mermaid diagram (expand to render)